by Van Bocxlaer K, Caridha D, Black C, Vesely B, Leed S, Sciotti RJ, Wijnant GJ, Yardley V, Braillard S, Mowbray CE, Ioset JR, Croft SL. International Journal for Parasitology: Drugs and Drug Resistance 2019, doi: 10.1016/j.ijpddr.2019.02.002
Summary: Three chemical lead series, the nitroimidazoles, benzoxaboroles, and aminopyrazoles have been identified as innovative treatments for visceral leishmaniasis. This study evaluated the anti-leishmanial efficacy of the lead compounds of each of these three chemical classes in in vitro and in vivo models of cutaneous leishmaniasis (CL). DNDI-VL-0690 (nitroimidazole), DNDI-1047 (aminopyrazole), and DNDI-6148 (benzoxaborole) showed excellent antileishmanial activity across a range of species in vitro and against L. major in mice. These compounds offer novel potential drugs for the treatment of CL.
